© Reuters.
WATERTOWN, Mass. – iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company, announced today the appointment of Jill DeSimone to its Board of Directors, effective tomorrow, where she will serve on the audit committee. The company, which is focused on developing a new generation of immuno-oncology therapeutics, emphasized the importance of adding experienced leaders to its board as it progresses towards later stages of development.
DeSimone brings over four decades of global business expertise in life sciences to iTeos. Most notably, she served as President of U.S. Oncology at Merck & Co., Inc., where she was instrumental in growing the division’s annual revenue to $9 billion from less than $500 million in eight years. Her tenure at Merck included leading several key product and indication launches, such as Keytruda®, the company’s fastest-growing product.
Prior to her role at Merck, DeSimone held the position of Senior Vice President of Global Women’s Health at Teva Pharmaceutical Industries (NYSE:), Ltd. Her career began at Bristol Myers (NYSE:) Squibb, where her roles culminated in the launch of Yervoy®, the first FDA-approved CTLA-4 immune checkpoint inhibitor. DeSimone’s current board memberships include Affini-T Therapeutics, Inc., Kinnate Biopharma Inc., Oncternal Therapeutics, Inc., Praxis Precision Medicine, Inc., and nonprofit organizations such as the Florida Cancer Specialists Foundation and Swim Across America.
Michel Detheux, Ph.D., president and CEO of iTeos, expressed enthusiasm over DeSimone’s appointment, highlighting the value of her insights for the company’s evolution. DeSimone, who earned a B.S. in Pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania, also commented on her commitment to aiding iTeos in achieving its goal of delivering transformational therapies to cancer patients.
iTeos Therapeutics is advancing a portfolio of therapeutic candidates targeting key immunological pathways involved in cancer, including the TIGIT/CD226 axis and the adenosine pathway. The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium.
This announcement is based on a press release statement and contains forward-looking statements regarding the potential benefits of product candidates and the company’s path to becoming a late-stage biopharmaceutical company. These statements are subject to risks and uncertainties, and actual results may differ materially.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
